Free Access
Med Sci (Paris)
Volume 28, Number 11, Novembre 2012
Page(s) 963 - 969
Section M/S Revues
Published online 12 November 2012
  1. Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000 ; 79 : 170–200. [CrossRef] [PubMed] [Google Scholar]
  2. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000 ; 79 : 155–169. [CrossRef] [PubMed] [Google Scholar]
  3. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010 ; 68 : 334–340. [PubMed] [Google Scholar]
  4. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 2008 ; 28 : 67–72. [CrossRef] [Google Scholar]
  5. Matute JD, Arias AA, Wright NAM, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009 ; 114 : 3309–3315. [CrossRef] [PubMed] [Google Scholar]
  6. Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci USA 2000 ; 97 : 4654–4659. [CrossRef] [Google Scholar]
  7. Levine S, Smith VV, Malone M, et al. Histopathological features of chronic granulomatous disease (CGD) in childhood. Histopathology 2005 ; 47 : 508–516. [CrossRef] [PubMed] [Google Scholar]
  8. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicro Agents Chemother 2006 ; 50 : 422–427. [CrossRef] [Google Scholar]
  9. Segal BH, Veys P, Malech H, et al. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011 ; 17 : S123–S131. [CrossRef] [PubMed] [Google Scholar]
  10. D’Angelo C, Luca A De, Zelante T, et al. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol 2009 ; 183 : 4609–4618. [CrossRef] [PubMed] [Google Scholar]
  11. Montagnoli C, Fallarino F, Gaziano R, et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol 2006 ; 176 : 1712–1723. [PubMed] [Google Scholar]
  12. Heitger A. Regulation of expression and function of IDO in human dendritic cells. Curr Med Chem 2011 ; 18 : 2222–2233. [CrossRef] [PubMed] [Google Scholar]
  13. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009 ; 114 : 2619–2622. [CrossRef] [PubMed] [Google Scholar]
  14. Beauté J, Obenga G, Mignot L Le, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011 ; 30 : 57–62. [CrossRef] [PubMed] [Google Scholar]
  15. Blumental S, Mouy R, Mahlaoui N, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011 ; 53 : e159–e169. [CrossRef] [PubMed] [Google Scholar]
  16. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998 ; 77 : 345–354. [CrossRef] [PubMed] [Google Scholar]
  17. Verweij PE, Varga J, Houbraken J, et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerging Infect Dis 2008 ; 14 : 566–572. [CrossRef] [PubMed] [Google Scholar]
  18. Verweij PE, Warris A, Weemaes CM. Preventing fungal infections in chronic granulomatous disease. N Engl J Med 2003 ; 349 : 1190–1191. [CrossRef] [Google Scholar]
  19. Wildenbeest JG, Oomen MW, Brüggemann RJ, et al. Rhizopus oryzae skin infection treated with posaconazole in a boy with chronic granulomatous disease. Pediatr Infect Dis J 2010 ; 29 : 578. [CrossRef] [Google Scholar]
  20. Ravin SS De, Challipalli M, Anderson V, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis 2011 ; 52 : e136–e143. [CrossRef] [PubMed] [Google Scholar]
  21. Machouart M, Garcia-Hermoso D, Rivier A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol 2011 ; 49 : 1681–1683. [CrossRef] [PubMed] [Google Scholar]
  22. Snelgrove RJ, Edwards L, Williams AE, et al. In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J Immunol 2006 ; 177 : 5509–5516. [PubMed] [Google Scholar]
  23. Verweij PE, Weemaes CM, Curfs JH, et al. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000 ; 38 : 3900–3901. [PubMed] [Google Scholar]
  24. Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007 ; 45 : 673–681. [CrossRef] [PubMed] [Google Scholar]
  25. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003 ; 348 : 2416–2422. [CrossRef] [PubMed] [Google Scholar]
  26. Hodiamont CJ, Dolman KM, Ten Berge IJM, et al. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 2009 ; 47 : 217–220. [CrossRef] [PubMed] [Google Scholar]
  27. Epaulard O, Leccia M-T, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect 2011 ; 41 : 594–601. [CrossRef] [PubMed] [Google Scholar]
  28. Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 ; 40 : 1684–1688. [CrossRef] [PubMed] [Google Scholar]
  29. The international chronic granulomatous disease cooperative study group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991 ; 324 : 509–516. [CrossRef] [PubMed] [Google Scholar]
  30. Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008 ; 126 : 155–164. [CrossRef] [PubMed] [Google Scholar]
  31. Stasia MJ. La granulomatose septique chronique X+ : un fabuleux modèle d’étude de l’activation du complexe NADPH oxydase. Med Sci (Paris) 2007 ; 23 : 526–532. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Gougerot-Pocidalo MA, El Benna J, My-Chan Dang P, Elbim C. Quand les polynucléaires neutrophiles attrapent les agents pathogènes dans leurs filets. Med Sci (Paris) 2007 ; 23 : 464–465. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Lamoth F, Bochud PY. Aspergillose invasive : perspectives en infectiologie préventive. Med Sci (Paris) 2009 ; 25 : 669–672. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. De Oliveira-Junior EB, Bustamante J, Newburger PE, Condino-Neto A. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol 2011 ; 73 : 420–427. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.